

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)



This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “*Company*”), together with its subsidiaries referred to as the “*Group*”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest

promotion, sales and distribution of the Drug. At the same time, Techdow USA agreed to purchase the Drug from CTTQ at an agreed price and share an agreed percentage of the net profit from the sale of the Drug with CTTQ.

The Drug is a neurokinin-1 receptor blocker used in the prevention and treatment of nausea and vomiting caused by highly emetogenic chemotherapy (HEC) regimens. It is generally recommended under international guidelines that the triple regimen of NK-1 receptor antagonist, 5-HT3 receptor antagonist and dexamethasone as the first-line antiemetic regimen.

